KRAS and neoplasm: When this drug was optimised for in vivo administration (BI-2493), tumour growth in colorectal cancer or PDAC cell line derived xenograft mouse models carrying KRAS G12C, G12D, G12V or A146V was slowed, and a tolerable toxicity profile seen (Kim et al., 2023).